Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | MVD | P53602 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25788481 | 0.87 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4PGK1 | |
| SCHEMBL25021047 | 0.80 | LPAR3 (0.34) | CHRNB2CHRNA4PGK1PGK2MVD | |
| SCHEMBL25762158 | 0.79 | MVD (0.35) | CA12CA1CA2CA9PGK1 | |
| SCHEMBL25657183 | 0.77 | LPAR3 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4MVD | |
| SCHEMBL23125478 | 0.77 | CHRNB2 (0.34) | CA12CA1CA2CA9CHRNB2 | |
| SCHEMBL25762731 | 0.76 | KDM4C (0.34) | CA12CA1CA2CA9PGK1 | |
| SCHEMBL38659094 | 0.76 | TPI1 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4MVD | |
| SCHEMBL25787110 | 0.76 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12516496 | 0.74 | ALDH1A1 (0.39) | CA12CA1CA2CA9CHRNB2 | |
| SCHEMBL6440136 | 0.74 | TSHR (0.42) | CA12CA1CA2CA9CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4134134-A1 | STING AGONISTIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | CA12 3162/4885CA1 4596/4885CA2 3284/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | CA12 4633/4885CA1 4533/4885CA2 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.